Skip to Content

David M. Gershenson, M.D.

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Professor, Obstetrics, Gynecology & Reproductive Sciences, The University of Texas Medical School, The University of Texas Health Science Center, Houston, TX

Bio Statement

As Professor of Gynecologic Oncology, I am engaged in several aspects of clinical and translational research. My personal research is focused on ovarian cancer. In collaboration with several clinical and basic science colleagues, I am conducting several clinical and translational studies of rare ovarian tumors: low-grade serous tumors (serous tumors of low malignant potential and low-grade serous carcinomas), clear cell carcinomas, mucinous carcinomas, malignant ovarian germ cell tumors, and sex cord-stromal ovarian tumors. Our studies in the front-line, neoadjuvant, and recurrent settlings have indicated that low-grade serous carcinomas are relatively chemoresistant. I am the principal investigator or co-principal investigator of clinical trials focused on novel therapeutics for patients with low-grade serous carcinoma of the ovary. Other studies from our group and other investigators have also reported the poor prognosis associated with advanced stage or recurrent ovarian clear cell and mucinous carcinomas.

Since 1999, I have served as Co-Principal Investigator of M.D. Anderson’s NCI-funded SPORE in Ovarian Cancer and as Co-Project Leader of Project 3, “Personalized Therapy for Women with Low-Grade Serous Carcinoma of the Ovary.” Funding for the third consecutive 5-year cycle of this grant was renewed in September 2010. This project includes preclinical studies designed to elucidate the pathogenesis of low-grade serous carcinoma and the development of clinical trials utilizing novel targeted agents based on the preclinical findings. The clinical trials are conducted through the NCI-sponsored cooperative group—the Gynecologic Oncology Group (GOG).

I continue to serve as Program Leader of the Gynecological Cancers Program of M.D. Anderson’s Cancer Center Support Grant (CCSG). I continue to play an active role in the leadership of the GOG. Since 2005, I have been the Chair of the GOG’s Rare Tumor Committee. During this period, the committee has completed patient accrual on a clinical trial of a novel targeted agent, a MEK inhibitor, for women with recurrent low-grade serous carcinoma of the ovary. Six other trials have been activated and are currently accruing patients. I am the Co-Principal Investigator on one of these trials and the Principal Investigator on an international trial between the GOG and a research group in UK for women with newly diagnosed mucinous carcinoma of the ovary. I also serve on the GOG’s Protocol Development Committee, which peer-reviews all clinical trials developed by the group. Since 2005, I have served as a member of the NCI’s Gynecologic Cancer Steering Committee, which approves all new phase III and randomized phase II clinical trials for gynecologic cancers in North America. In July 2010, I was elected as one of three Co-Chairs of this committee for a 3-year term. I continue to serve as Co-Chair of the Rare Tumor Working Group of the Gynecologic Cancer Intergroup (GCIG), an international consortium of 23 world-wide cooperative groups focused on gynecologic malignancies. In June 2010, I participated in a consensus conference on ovarian cancer in Vancouver, BC, sponsored by GCIG. Since March 2009, I have served as Chairman of the Foundation for Women’s Cancer (formerly the Gynecologic Cancer Foundation), a national foundation of the Society of Gynecologic Oncologists, whose major missions include research grant funding and public education and awareness of gynecologic cancers. My other major national activities include serving as Editor Emeritus of the journal, Gynecologic Oncology, and as a Director of the American Board of Obstetrics and Gynecology.

Office Address

The University of Texas MD Anderson Cancer Center
P.O. Box 301439
Unit Number: 1362
Houston, TX 77230-1439
Phone: 713-745-2565

Education & Training

Degree-Granting Education

1971 Vanderbilt School of Medicine, Nashville, TN, MD, Medicine
1967 University of Pennsylvania, Philadelphia, PA, BA, Psychology

Postgraduate Training

7/1977-6/1979 Fellowship, Gynecologic Oncology, U.T. M. D. Anderson Hospital and Tumor Institute, Houston, TX, Dr. Felix N. Rutledge
7/1972-6/1975 Residency, Obstetrics & Gynecology, Yale-New Haven Hospital, New Haven, CT, Dr. Nathan Kase
6/1971-6/1972 Internship, Medicine/Surgery, University of Iowa Hospital, Iowa City, IA, Dr. Robert Condon

Board Certifications

1977 American Board of Obstetrics and Gynecology, Diplomate, Recertification Date: 1991
1981 American Board of Obstetrics and Gynecology, Diplomate, Division of Gynecologic Oncology
1972 National Board of Medical Examiners, Diplomate


Academic Appointments

Courtesy Status, Obstetrics and Gynecology Service, St. Luke's Episcopal Hospital, Houston, TX, 9/2000-present

Administrative Appointments/Responsibilities

Department Chair, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-11/2012

Other Appointments/Responsibilities

Member, Gynecologic Cancer Steering Committee, National Cancer Institute, Bethesda, MD, 2006-present
Member, Medical Advisory Board, fertileHope, New York, NY, 2003-2009
Member, Medical Advisory Board, Cancer Research and Prevention Foundation, Alexandria, PA, 2001-present
Member, Ovarian Cancer Working Group, Prognostic Factors Consensus Conference, American Joint Committee on Cancer, Chicago, IL, 1998
Member, Ovarian Cancer Practice Guidelines Committee, The National Comprehensive Cancer Network, Jenkintown, PA, 1997-2007

Institutional Committee Activities

member, Planning Committee for the 5th Annual Cancer Symposium, 11/2008-7/2009
Member, Endowed Positions and Awards Committee, 10/2008-8/2011
Chairman, Oversight Committee/Approval Committee for Tissue Distribution, Multidisciplinary Gynecologic Cancer Translational Research Tumor Bank, 1999-present
Chair, Executive Committee, Blanton-Davis Ovarian Cancer Research Program, 1996-2007

Honors and Awards

2006-2009 Who's Who in Science and Engineering, Marquis Who's Who
2004-2005 Guide to America's Top Obstetricians and Gynecologists
2001-2002 Best Doctors: Information When It Matters Most, Peer-selection
1997-1999 Who's Who in the South and Southwest, Marquis Who's Who
1995 Favorite Son Award, Southern Illinois Medical Association
1992 President's Award, Society of Gynecologic Oncologists
1971 Alpha Omega Alpha, Vanderbilt School of Medicine

Professional Memberships

American Board of Obstetrics and Gynecology
Chair, Long Range Planning Committee, 2006-2014
Member, Credentials Committee, 2006-2014
Director, Division of Gynecologic Oncology, 2002-2005
Member, Board of Directors, 2002-2005
Member, Division of Gynecologic Oncology, 1999-2005
Examiner, Division of Gynecologic Oncology, 1996-2011
Examiner, 1994-2011
American College of Surgeons
Liaison Member, OB/GYN Advisory Council, 2004-2005
American Radium Society
President, 2000-2001
American Society of Clinical Oncology
Education Committee, 2006-2009
Roster of Cancer Experts, 2005-present
Member, Surgical Oncology Task Force, 2001
Association of Professors of Gynecology and Obstetrics, Crofton, MD
Member, 2003
Felix Rutledge Society
President, 1994-1995
Harris County Medical Society
Member, 1979-present
Houston Gynecological and Obstetrical Society
President, 1998
Executive Committee, 1994-present
Secretary, 1994-1995
Houston Surgical Society
Member, 1980-present
Society of Gynecologic Oncologists
Member, Strategic Planning Taskforce, 2001
Chair, Nominating Committee, 1998
President, 1996
Secretary-Treasurer, 1990-1994

Selected Publications

Peer-Reviewed Original Research Articles

1. Gershenson DM, Sun CC, Bodurka DC, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52, 7/2009. e-Pub 4/2009. PMID: 19361839.
2. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol 113(1):86-90, 4/2009. e-Pub 1/2009. PMID: 19162310.
3. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510-514, 3/2008. e-Pub 12/2007. PMID: 18155273.
4. Gershenson D, Miller A, Champion V, Monahan P, Zhao Q, Cella D, Williams S. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: A Gynecologic Oncology Group study. J Clin Oncol 25(19):2792-2797, 7/2007. PMID: 17602084.
5. Crotzer D, Sun C, Coleman R, Wolf J, Levenback C, Gershenson D. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2):404-408, 2007. e-Pub 2/2007. PMID: 17292461.

Books (edited and written)

1. Gershenson DM, Co-Editor. Ed(s) V. Katz, G. Lentz, R. Lobo, D. Gershenson. Comprehensive Gynecology, 5th Ed. Elsevier, 2007.
2. Gershenson DM, Co-Editor. Ed(s) P.J. Eifel, D.M. Gershenson, J.J. Kavanagh, E.G. Silva. Gynecologic Cancer. Springer, 2005.
3. Gershenson DM, Senior Editor. Ed(s) D.M. Gershenson, W.P. McGuire, M. Gore, G. Thomas and M. Quinn. Gynecologic Cancer: Controversies in Management. Churchill Livingstone Publishers, 2004.
4. Gershenson DM, Co-Editor. Ed(s) R.R. Barakat M.W. Bevers, D.M. Gershenson, W. J. Hoskins. Handbook of Gynecologic Oncology, 2nd Ed. Martin Dunitz Publishers, Ltd., 2002.
5. Gershenson DM, Co-Editor. Ed(s) D.M. Gershenson, A.H. DeCherney, S.L. Curry, and Linda Brubaker. Operative Gynecology, 2nd Ed. W.B. Saunders, 2001.
6. Gershenson DM, Co-Editor. Ed(s) R.R. Barakat, M.W. Bevers, D.M. Gershenson, W. J. Hoskins. Handbook of Gynecologic Oncology. Martin Dunitz Publishers, Ltd., 2000.
7. Gershenson DM, Co-Editor. Ed(s) D.M. Gershenson, W.P. McGuire. Ovarian Cancer: Controversies in Management. Churchill Livingstone, 1997.
8. Gershenson DM. Ed(s) Gershenson DM, Co-Editor. Cancer in Pregnancy. In: Cancer Bulletin, 1994.
9. Gershenson DM. Obstetrics & Gynecology Clinics of North America. Gershenson DM, Guest Editor, 1994.
10. Gershenson DM. Ed(s) D.M. Gershenson, A.H. DeCherney, and S.L. Curry. Operative Gynecology. W. B. Saunders Co., 1994.
11. David Gershenson, Associate Editor. Ed(s) N.G. Kase, A.B. Weingold, D.M. Gershenson. Principles and Practice of Clinical Gynecology, 2nd Ed. Churchill Livingstone, 1990.
12. Gershenson DM. Ed(s) F.N. Rutledge, R.S. Freedman, D.M. Gershenson. Gynecologic Cancer: Diagnosis and Treatment Strategies. University of Texas Press: Austin, 1986.

Grant & Contract Support

Title: Training of Academic Gynecologic Oncologists
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/15/2005 - 8/31/2010

Last updated: 6/15/2015